Valuation: Dyne Therapeutics, Inc.

Capitalization 1.42B 1.35B 1.27B 1.12B 2.01B 123B 2.23B 15.13B 5.61B 51.28B 5.31B 5.2B 215B P/E ratio 2024 *
-4.01x
P/E ratio 2025 * -3.7x
Enterprise value 800M 761M 718M 634M 1.13B 69.27B 1.26B 8.55B 3.17B 28.97B 3B 2.94B 122B EV / Sales 2024 *
-
EV / Sales 2025 * -
Free-Float
98.81%
Yield 2024 *
-
Yield 2025 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day-1.00%
1 week-9.50%
Current month-2.18%
1 month-7.27%
3 months-54.11%
6 months-68.30%
Current year-40.96%
More quotes
1 week
13.07
Extreme 13.07
15.43
1 month
13.07
Extreme 13.07
17.18
Current year
13.07
Extreme 13.07
26.22
1 year
13.07
Extreme 13.07
47.45
3 years
4.30
Extreme 4.3
47.45
5 years
4.30
Extreme 4.3
47.45
10 years
4.30
Extreme 4.3
47.45
More quotes
Director TitleAgeSince
Chief Executive Officer 62 2024-03-24
Director of Finance/CFO 39 2020-06-30
Chief Tech/Sci/R&D Officer 58 2024-09-02
Manager TitleAgeSince
Director/Board Member 61 2018-10-31
Chairman 55 2018-10-31
Director/Board Member 50 2018-10-31
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi.($)
-1.00%-9.50%-42.50%+113.34% 1.42B
-0.77%-2.20%+9.84%+98.50% 118B
-0.10%-5.13%-28.93%+8.03% 72.09B
-2.13%-3.83%+68.23%+140.90% 38.79B
-2.40%+1.89%+31.02%-22.46% 28.73B
+2.38%+3.29%+58.26%+12.45% 24.63B
+4.61%+2.25%+11.97%-30.27% 23.61B
-2.06%+6.27%+380.22%+952.71% 15.76B
+0.81%-0.80%+189.03%+244.83% 14.19B
+0.94%+8.59%-19.89%-31.61% 13.46B
Average +0.03%+0.01%+65.73%+148.64% 35.05B
Weighted average by Cap. -0.26%-1.19%+36.16%+99.35%
See all sector performances

Financials

2024 *2025 *
Net sales - -
Net income -326M -311M -293M -259M -462M -28.26B -513M -3.49B -1.29B -11.82B -1.22B -1.2B -49.6B -411M -391M -369M -326M -582M -35.57B -646M -4.39B -1.63B -14.88B -1.54B -1.51B -62.44B
Net Debt -616M -586M -553M -488M -873M -53.36B -968M -6.58B -2.44B -22.31B -2.31B -2.26B -93.66B -492M -468M -442M -390M -697M -42.63B -774M -5.26B -1.95B -17.82B -1.84B -1.81B -74.83B
More financial data * Estimated data
Logo Dyne Therapeutics, Inc.
Dyne Therapeutics Inc. is a clinical-stage muscle disease company. It is focused on advancing life-transforming therapeutics for people living with genetically driven diseases. It is utilizing its FORCE platform to overcome the limitations of muscle tissue delivery and oligonucleotide therapeutics for muscle diseases. Its FORCE platform therapeutics consist of an oligonucleotide payload that is designed to target the genetic basis of the disease. Using its FORCE platform, it is assembling a portfolio of muscle disease therapeutics, including its lead programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral dystrophy (FSHD). Its therapeutics consist of three components: a Fab, a clinically validated linker, and an oligonucleotide payload that it attaches to its Fab using the linker. It also plans to expand its portfolio through development efforts focused on rare skeletal muscle diseases, as well as cardiac and metabolic muscle diseases.
Employees
173
More about the company
Date Price Change Volume
25-02-14 13.91 $ -1.00% 984,219
25-02-13 14.05 $ +0.93% 1,002,739
25-02-12 13.92 $ +2.96% 1,460,523
25-02-11 13.52 $ -6.63% 1,754,910
25-02-10 14.48 $ -5.79% 1,276,829

Delayed Quote Nasdaq, February 14, 2025 at 04:00 pm EST

More quotes
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
13.91USD
Average target price
49.50USD
Spread / Average Target
+255.86%
Consensus

Quarterly revenue - Rate of surprise